Filing Details

Accession Number:
0001415889-24-019906
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-07-22 20:22:03
Reporting Period:
2024-07-22
Accepted Time:
2024-07-22 20:22:03
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1817241 Artiva Biotherapeutics Inc. ARTV Biological Products, (No Disgnostic Substances) (2836) 863614316
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1931083 Yong-Jun Huh C/O Artiva Biotherapeutics, Inc.
5505 Morehouse Drive, Suite 100
San Diego CA 92121
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2024-07-22 667,185 $0.00 1,016,022 No 4 C Indirect By GC Corp.
Common Stock Acquisiton 2024-07-22 330,095 $0.00 1,346,117 No 4 C Indirect By GC Corp.
Common Stock Acquisiton 2024-07-22 294,117 $10.20 1,640,234 No 4 J Indirect By GC Corp.
Common Stock Acquisiton 2024-07-22 1,666,666 $12.00 3,306,900 No 4 P Indirect By GC Corp.
Common Stock Acquisiton 2024-07-22 292,791 $0.00 525,349 No 4 C Indirect By GC Cell Corporation
Common Stock Acquisiton 2024-07-22 62,181 $0.00 587,530 No 4 C Indirect By GC Cell Corporation
Common Stock Acquisiton 2024-07-22 256,316 $10.20 843,846 No 4 J Indirect By GC Cell Corporation
Common Stock Acquisiton 2024-07-22 416,666 $12.00 1,260,512 No 4 P Indirect By GC Cell Corporation
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 C Indirect By GC Corp.
No 4 C Indirect By GC Corp.
No 4 J Indirect By GC Corp.
No 4 P Indirect By GC Corp.
No 4 C Indirect By GC Cell Corporation
No 4 C Indirect By GC Cell Corporation
No 4 J Indirect By GC Cell Corporation
No 4 P Indirect By GC Cell Corporation
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Series A Preferred Stock Disposition 2024-07-22 667,185 $0.00 667,185 $0.00
Common Stock Series B Preferred Stock Disposition 2024-07-22 330,095 $0.00 330,095 $0.00
Common Stock Series A Preferred Stock Disposition 2024-07-22 292,791 $0.00 292,791 $0.00
Common Stock Series B Preferred Stock Disposition 2024-07-22 62,181 $0.00 62,181 $0.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
0 No 4 C Indirect
Footnotes
  1. Each share of Series A Preferred Stock and Series B Preferred Stock (collectively, the "Preferred Stock") converted into shares of Common Stock of the Issuer on a one-for-one basis without payment of further consideration. Upon the closing of the Issuer's initial public offering (the "IPO"), the Preferred Stock wasconverted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.
  2. The shares are held directly by GC Corp. Mr. Yong-Jun Huh is Chief Executive Officer of GC Corp. GC Corp., a public Korean holdings company, is ultimately controlled by its board of directors, consisting of Mr. Yong-Jun Huh, Huh II-Sup, Park Yong-Tae and Kim Seok-Hwa. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and each disclaims beneficial ownership of all shares held by such entity, except to the extent of any pecuniary interest therein.
  3. Represents the conversion of outstanding simple agreement for future equity in the amount of $3,000,000.00 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price.
  4. The shares were purchased in the Issuer's initial public offering.
  5. The shares are held directly by GC Cell Corporation. Mr. Yong-Jun Huh is Chief Executive Officer of GC Corp. GC Corp., a public Korean holdings company, which is the parent company of GC Cell Corporation and is ultimately controlled by its board of directors, consisting of Mr. Yong-Jun Huh, Huh II-Sup, Park Yong-Tae and Kim Seok-Hwa. Each of these individual directors of GC Corp. may be deemed to share voting and investment power over the shares held by GC Corp. and GC Cell Corporation and each disclaims beneficial ownership of all shares held by such entities, except to the extent of any pecuniary interest therein.
  6. Represents the conversion of outstanding simple agreement for future equity in the amount of $2,614,424.28 into shares of the Issuer's common stock upon closing of the Issuer's IPO at a 15% discount to the IPO price.